Autism spectrum disorders (ASDs) are common, heritable neurodevelopmental conditions. The genetic architecture of ASDs is complex, requiring large samples to overcome heterogeneity. Here we broaden coverage and sample size relative to other studies of ASDs by using Affymetrix 10K SNP arrays and 1,181 families with at least two affected individuals, performing the largest linkage scan to date while also analyzing copy number variation in these families. Linkage and copy number variation analyses implicate chromosome 11p12-p13 and neurexins, respectively, among other candidate loci. Neurexins team with previously implicated neuroligins for glutamatergic synaptogenesis, highlighting glutamate-related genes as promising candidates for contributing to ASDs.
Autism is a neurodevelopmental disorder characterized by impairments in reciprocal social interaction, communication deficits and repetitive and restricted patterns of behavior and interests. Autistic disorder is the prototypical pervasive developmental disorder (PDD or, equivalently, ASD), which form a group that also includes Asperger disorder, PDD not otherwise specified and Rett disorder 1 . Population prevalence of autism is approximately 15-20 in 10,000, and all ASDs affect about 60 in 10,000 children. Worldwide, males are affected four times as often as females 2 . Autism is associated with a recognized cause in only about 10% of individuals, most commonly with fragile X syndrome, tuberous sclerosis and chromosomal abnormalities 3, 4 .
Twin studies show a concordance of 60%-92% for monozygotic twins and 0%-10% for dizygotic pairs, depending on phenotypic definitions 5 . Milder phenotypes are similarly elevated in relatives of singleton probands, consistent with a spectrum of severity 6 . The estimated prevalence of autism in siblings is 5%-10% (refs. 7,8) . The ratio of sibling recurrence risk to population prevalence varies from 67 to 25, both larger than for most multifactorial diseases. Although familial clustering in autism could reflect shared environmental factors, twin studies 5, 9 and the distribution of milder phenotypes in families favors a model involving multiple interacting loci 10, 11 . We hypothesize that liability to autism is due, in large part, to oligogenic inheritance in which combinations of susceptibility alleles contribute. Variation in phenotypic severity of sibling pairs and family members ascertained through an autistic proband are both consistent with this hypothesis. Based on numerous observations of karyotypic abnormalities in autism, we also hypothesize that submicroscopic alterations are involved.
Genome-wide linkage scans 12 (also reviewed in ref. 13 ) for autism susceptibility loci have identified chromosomal regions 2q, 7q and 17q, with 7q yielding the most consistently positive results, including support from meta-analysis. Moreover, substantial evidence suggests that chromosomal abnormalities contribute to autism risk, but the exact prevalence is unclear because literature surveys span different diagnostic and cytogenetic approaches and sample sizes. Recent surveys 3, 4 show a mean rate of gross mutations and chromosomal abnormalities between 4.3% (78/1,826) and 7.4% (129/1,749), but many studies find rates of detected abnormalities in 5%-10% of affected individuals 3 . Among the most frequent findings are fra(X)(q27) (3.1%; 28/899) and anomalies involving proximal 15q (0.97%; 17/1,749), specifically the Prader-Willi and Angelman region 3, 4 . Duplications of 15q11-q13, typically of maternal origin, are observed in 1%-3% of cases, either as interstitial duplications or supernumerary isodicentric marker chromosomes containing one or two extra copies of this region 3 . Linkage, association, and/or chromosome rearrangement studies have identified several ASD candidates, including genes encoding neuroligins and their binding partners, as having disease-associated mutations [14] [15] [16] [17] .
In our model for autism, combinations of multiple loci that possibly interact and microscopic or submicroscopic chromosomal abnormalities contribute to risk, complicating the detection of individual loci. Increasing the likelihood of detecting loci requires analyzing a large sample of multiplex families (i.e., families with two or more affected individuals), thereby enhancing the power of linkage analysis and controlling sources of etiologic heterogeneity (herein, the term families implies multiplex families).
We have assembled a sample of over 1,400 ASD families, a resource sufficiently large to implement multiple strategies for localizing susceptibility loci (see 'Power' in Supplementary Methods online). Although some linkage studies have attempted to control for heterogeneity attributable to chromosomal abnormalities by excluding the small number of affected families, none has attempted to merge © 2007 Nature Publishing Group http://www.nature.com/naturegenetics linkage analysis with studies of fine-level chromosomal variation. We have developed an approach, using comparative analysis of hybridization intensities, to identify submicroscopic copy number variations (CNVs) as putative risk loci and as a tool to stratify the samples to reduce genetic heterogeneity for linkage analyses.
RESULTS

Individuals with ASD
The Autism Genome Project (AGP) Consortium, comprising scientists from 50 centers in North America and Europe, collected 1,496 ASD families (7,917 family members) for this study. Diagnosis was based on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) or clinical evaluation (see ref. 18 and Methods). Origins of the individuals screened are shown in Supplementary Methods; most were karyotyped (B71%) and screened for fragile X mutations (B94%), and families were excluded if either was abnormal in at least one affected individual. Most cell lines or DNA samples arising from the project are available at the National Institute for Mental Health (NIMH) Center for Collaborative Genetic Studies, the European Collection of Cell Cultures and the Autism Genetics Research Exchange. We genotyped genomic or in some cases whole genome-amplified (WGA) DNA.
Linkage analysis by diagnostic group
We successfully generated genotypes from 1,491 of 1,496 nominal families (6,709 samples; Table 1 ) using the Affymetrix 10K v2 SNP array. WGA had no discernible impact on genotyping accuracy: for 12 duplicate samples assessed, concordance of genotypes for WGA versus blood DNA was 499.6% with no significant difference in completion rates (both B94%). From the 10,112 SNPs initially genotyped, quality control procedures resulted in marker exclusion for the following reasons: minor allele frequency o0.05 (removed 749 SNPs), high rate of missing genotypes (removed 1,112 SNPs), selection of tag SNPs (removed 1,734 SNPs) and deviations from Hardy-Weinberg Equilibrium (removed 391 SNPs). Following quality control, the discordant call rate per locus, based on 261 duplicate samples, was roughly 5/10,000.
Quality control on family data had a similar impact on reducing numbers (Table 1) , yielding 1,181 families for linkage analysis. Of these families, we estimate that 64% were included in smaller, published linkage studies. The families were distributed across three diagnostic categories (narrow, broad and heterogeneous ASD (hASD)), which were defined according to the distribution of diagnosis (see Methods). Linkage analyses were performed for three nested diagnostic groupings (narrow, broad and all families); for analyses focusing on one diagnostic group, 'broad' is a reasonable choice because a substantial number of families fall in the group, and the sensitivity and specificity of this diagnostic method are reliable 18 .
Before linkage analyses, we rebuilt the Affymetrix genetic map by linear interpolation from National Center for Biotechnology Information Build35 and markers of known genetic positions 19 to infer genetic locations for all SNPs. We then validated the new genetic map using the linkage data.
Linkage information, as reported by MERLIN, averaged B95% over the genome (minima at telomeres, Z71%) because of high coverage of markers across the genome and availability of parental genotypes (3% of families have no parental genotypes, whereas 79% have genotypes for both parents). Thus, the results are also insensitive to SNPs in linkage disequilibrium (see Methods). Only for all families does statistical evidence exceed the threshold for suggestive linkage 20 , at 11p12-p13 (Fig. 1) .
Characterization of copy number variation
We assessed our samples for CNV content using signal intensities obtained from the SNP arrays. Because the distribution of intensity is continuous, whereas copy numbers are discrete, an algorithm is required to infer copy number from signal intensity of a SNP genotype relative to intensity from other samples. Initially, to capture as many CNVs as possible, we used two approaches (termed 'batch' and 'plateby-plate') for intensity comparisons, which yielded a total of 2,788 putative CNVs from 1,109 samples from 715 families ( Table 2) define a more stringent set of CNV calls, we examined the raw intensity data from 42 CNV calls that were presumed real based on overlap with non-mendelian genotype errors or by laboratory experimentation. We also assessed samples having identical CNVs within the same family, as these could also be considered to be validated calls. Fig. 2 ).
Caveats about these data are as follows: (i) there will be bona fide CNVs in the batch comparison data that fail to meet cutoffs in the filtered analysis; (ii) some CNVs could be somatic artifacts, such as cell culture-induced rearrangements and aneuploidy; (iii) the mapping resolution of CNV boundaries is dependent on local SNP density and is therefore nonuniform; (iv) smaller CNVs will be more likely to be missed ( Supplementary  Fig. 1 online) and (v) balanced rearrangements will not be detected.
Considering solely our highest confidence data, we identified 254 CNVs in 196 ASD cases from 173 families ( Table 2 , Fig. 2 and Supplementary Tables 2 and 3 online). The average and median sizes were 3.4 Mb and 0.66 Mb, respectively, and the majority (66%) were CNV gains, probably owing to a greater tolerance in the genome for large gains versus deletions. The observations most relevant to ASD disease risk (Supplementary Table 1 ) included (i) the identification of ten families with apparent de novo CNVs (in three such families, the CNV was found in both ASD sibs); (ii) 18 CNVs in unrelated affected individuals having genomic locations coincident with published ASD chromosome rearrangements and (iii) 126 CNVs with recurrent (47) or overlapping (79) boundaries, suggesting they could be nonrandom events (Supplementary Tables 3 and 4 online). We also detected seven samples from three families with ASD-associated chromosome 15q gains, all of which were maternally inherited, as would be expected (including at least two that escaped earlier karyotypic detection).
We highlight four CNV discoveries to demonstrate the utility and complexity of this data and also to serve as a prototype of how this new type of genetic information can be used in mapping studies. First, in family AS049, two female sibs with ASD had apparently identical 300-kb CNV losses of chromosome 2p16 not detected in either parent. Quantitative PCR analysis confirmed the microdeletion: microsatellite analysis showed the identical maternal chromosomal segment but no paternal DNA in the sibs, providing a likely explanation of paternal gonadal mosaicism. This hemizygous deletion eliminates coding exons from the neurexin 1 gene (NRXN1), which represents a functional © 2007 Nature Publishing Group http://www.nature.com/naturegenetics a,b,c,d CNV analysis for the arrays was performed using three approaches: after trimming the data set with the first-pass cutoffs, arrays were renormalized and analyzed using a 'batch comparison' (B1,000 scans; footnote b) or by a 'plate-by-plate' comparison (96 scans; footnote c) to avoid potential plate-specific batch effects. In the most stringent analysis (footnote d), thresholds were set based on validation data (see footnote n below) to minimize potential for false positives. We note that although column 4 contains data from the most stringent analysis, there are some CNVs found exclusively in one or both of columns 2 and 3 that are indeed real. All data can be viewed at the Autism Chromosome Rearrangement Database (see URL in Methods). e Range of CNV size: batch (100 bp to 240 Mb), plate-by-plate (100 bp to 134 Mb), filtered (100 bp to 134 Mb); distributions are shown in Supplementary Figure 1 . f CNVs in affected individuals that were inherited from either parent. g CNVs present in two or more affected siblings that are either de novo or inherited. h CNVs in affected individuals that are de novo in origin with the total number of de novo events occurring in siblings in brackets. i CNVs that are familial and recurrent. j CNV gains or CNV losses with the same coordinates found in two or more unrelated families (a recurrent CNV gain and CNV loss at the same site is only counted once). k Two or more CNV gains or CNV losses with overlapping genomic coordinates (a CNV gain and CNV loss combination is not counted). l CNVs that overlap with mapped chromosome rearrangement breakpoints annotated in the Autism Chromosome Rearrangement Database. m CNVs that overlap with other CNVs not known to be associated with disease as catalogued in the Database of Genomic Variants (see URL in Methods). We note that some CNVs found in the DGV could be predisposing or disease related. n Total number of validated CNVs. A CNV was considered validated if it overlapped with mendelian genotype errors or if it was confirmed using an independent set of experiments (for example, karyotyping, quantitative PCR, array-CGH or Affymetrix 500K Mapping arrays) (Supplementary Table 4 ). o Number of families belonging to the group of 1,168 families passing data cleaning that were removed from linkage analysis. Families were only removed if at least one affected individual contained a CNV not found in the Database of Genomic Variants.
candidate for ASD based on the role of NRXN1 in synaptogenesis and its interaction with neuroligins. Rare NRXN1 mutations apparently generate risk for ASD and mental retardation 16, 22, 23 . Both girls presented with typical autism, including characteristic developmental delays. Although we could not be certain of their verbal status because of their young age, one appeared nonverbal, whereas her sister had mild language regression. Neither parent had clinically important features. Second, we found a recurring 1.1-Mb CNV gain at chromosome 1q21 in three families: AS048, with one affected male; AS039, one affected female; and AS007, two affected male sibs and their father of unknown affection status. It overlaps the same region implicated in mental retardation and other anomalies 21, 24, 25 .
Third, we observed CNVs of B933 kb at 17p12 as a de novo duplication in an affected male-female sib pair in one family (AS068), as a maternally inherited deletion in two affected male sibs (AS028) and as a paternally inherited deletion in an affected female (AS001). This interval, when duplicated, causes Charcot-Marie-Tooth 1A (CMT1A) and when deleted causes hereditary neuropathy with liability to pressure palsy 26 . This region also overlaps with microdeletions seen in some cases of Smith-Magenis syndrome, which itself has phenotypic overlap with ASDs 27 . Moreover, other microduplications of the same interval have been described in individuals with mental retardation, speech and language delay, autism and related phenotypes 28 . None of the implied disease-associated CNVs described above were observed in any known control sample database, which at the time of the study comprised B500 samples from the general population 21, 29 .
Finally, we detected further complexity in two families with duplications of 22q11.2. In family AS063, the male proband diagnosed with autism inherited the duplication from his father, but a brother with PDD not otherwise specified does not have the duplication. In family AS019, the female sib diagnosed with autism carried the duplication, whereas an affected brother did not, and we did not observe the duplication in either parent. Genotyping confirmed the biological parents. FISH analysis confirmed duplications in both families and showed that it was de novo in the second family (data not shown).
Exploration of linkage by subsets of the data Linkage analysis identifies regions harboring one or more genetic variants that account for a substantial portion of risk in families. Rare de novo or familial CNVs that confer risk for ASDs could be a source of noise or heterogeneity that decreases sensitivity in linkage analyses. Thus, in theory, linkage signals from major loci could be amplified if families with rare CNV risk alleles were removed. A sound strategy to evaluate subsets based on known and putative CNVs, however, is unclear. Consider our three levels of CNV discovery (namely, filtered, plate and batch), which are ordered by degree of stringency of evidence required to call a CNV. Moving from filtered to batch, it is reasonable to assume that the rate of false positives is increasing while the rate of false negatives is potentially decreasing. Selecting a single approach a priori favors a certain, unknown ratio of false positives to false negatives. This ratio might not be optimal, depending on how much of the attributable risk for ASDs accrues to CNVs: if CNVs account for a large fraction of the risk, the false negative rate is critical; conversely, if CNVs account for a small fraction of the risk, then the false positive rate is of greater importance. For this reason, we chose to explore the effects of all three levels of CNV discovery. Within each level, we removed families in which at least one individual was diagnosed with ASD and also carried at least one putative CNV ( Table 3) . Using the broad diagnostic group, we recomputed the linkage traces ( Supplementary Fig. 2 Figure 2 Chromosome ideogram depicting 253 inferred CNVs found in 196 individuals with ASDs. These CNVs are derived from the highest stringency 'filtered' data set, but many other true CNVs will also be found in the other analyses and should be examined further. Characteristics of the complete data set are described in Table 2 . Some of the larger changes could represent somatic artifacts or missed karyotypic anomalies. All data are also downloadable or can be viewed in Genome Browser format at the Autism Chromosome Rearrangement Database (see URL in Methods). As additional analyses and validations are performed, the data will be posted at the same site. a A larger fraction of families tends to be removed from the more stringently diagnosed groups (narrow and broad) and from female-containing families, but neither trend approaches significance when the data are fitted to a log-linear model.
After removing 'CNV families' , the data becomes suggestive for linkage in two regions, 11p12-p13 and 15q23-25.3 (Fig. 3) , contrary to results from all broad families. The most noteworthy impact occurs for the batch method, which removes the greatest fraction of families. When families removed versus retained by the batch method are contrasted for identity-by-descent (IBD), heterogeneity is modest except for the 15q25.3 region (Fig. 3) .
The 4:1 ratio of affected males to females, higher reported recurrence risk for siblings of female versus male probands 8 and published literature 30, 31 suggest that a useful partition of the ASD families would be whether they contained affected females ('female-containing') or only affected males ('male-only'). Thus, we partitioned the families according to these criteria and recomputed linkage traces for each of the three nested groupings of diagnosis (Fig. 4) . Consistent with theory 32 , the female-containing families seem to be more informative for linkage. For instance, for the narrow diagnostic scheme, linkage traces cross the suggestive threshold three times, at 5p15.33, 9p24.1 and 11p13-12, whereas the traces do not approach this threshold for male-only families. Linkage traces for male-only families cross the suggestive threshold only for the most inclusive diagnostic level (5q12.3 and 9q33.3; Fig. 4 ) but not at the same locations as femalecontaining families. Although the differences between female-containing and male-only families in terms of linkage could be due to chance, tests of heterogeneity of IBD uncover substantial heterogeneity in 9p, 9q and 11p and modest heterogeneity in 5q (Fig. 4) .
Dividing the data into subsets according to presence of CNVs and according to sex of affected individuals seems to generate more informative linkage signals. To test whether combining both approaches to form subsets would also be useful, we used the broad diagnostic grouping. Linkage using these six subsets (Table 3) , female-containing versus male-only by three levels of CNV discovery, provides even more support for a risk locus in the vicinity of 11p12-p13 in femalecontaining families (Fig. 5) . female-containing families (Fig. 5) , and the maximum at 11p12-p13 approaches genome-wide significance (4.03 versus 4.1). Affected individuals in female-containing families have a slightly elevated rate of CNV detection (2%-3%) relative to male-only families, regardless of CNV-calling method, and the broad diagnostic group of families has a similarly elevated rate of CNV detection relative to hASD; the 'paired' rates are not significantly different, nor is the interaction of these variables a significant predictor of the presence or absence of a detected CNV (data not shown). Families participating in the AGP studies vary in their ancestry. To evaluate whether linkage would be strengthened by analyzing families of relatively homogeneous ancestry, we restricted the sample to 'European ancestry' , as inferred by principal components 33 of SNP genotypes. We inferred that all founders in 995/1,168 (85.2%) families were of European origin ( Supplementary Fig. 3 online) ; inferred ancestry agreed with available self-reports (99.6%). Using this sample, we repeated all linkage analyses in Figures 1 and 3-5 .
Exclusion of non-European families generally had only a modest impact on the results (see Supplementary Fig. 4 online for complete results). Linkage traces at chromosome 11p remained prominent, especially for female-containing families, although the linkage region for 11p was much broader. By using the batch results to remove 'CNV families' , a new region of suggestive linkage emerged: namely, 4q31.22, which also shows substantial heterogeneity of IBD (P o 0.00006) between retained and removed families. For all male-only families, the normalized likelihood ratio statistic for linkage (Z lr ) ¼ 3.85 at 9q33.3. In addition, previously reported locations for linkage, especially 2q and 7q, gained more support from this 'European' subset of the data. For example, linkage traces approached genome-wide suggestive linkage at 2q31.1 (female-containing, narrow) and 7q22.2 (male-only, broad).
DISCUSSION
The results obtained from scanning the genomes of the largest cohort of ASD families yet assembled delineate a new understanding of the genetic basis for this complex disorder. It is widely understood that risk for ASD arises in small part from chromosomal copy number abnormalities (CNAs), such as duplications of chromosome 15q11-q13. Yet, for nuclear families containing two or more affected individuals and prescreened for microscopic CNAs, linkage analyses have implicitly assumed other CNAs would have little if any role in the heritable component of ASD. Our CNV results lie in stark contrast with this view. Instead, we find an appreciable number of families that could be assessed (68/590 or 11.5%, 36/476 or 7.6% and 34/350 or 9.7% in the batch, plate or filter analyses, respectively; Table 2 ), in which all affected individuals share possibly detrimental abnormalities (that is, possible CNAs). Owing to the relatively wide and uneven spacing of SNPs and our conservative approach of calling CNVs, we have missed many other events of this kind. By contrast, we also find a number of families in which only one of the affected relatives has a detected CNA. One possible implication of this finding is that, in these cases, relevant CNVs might be risk factors and not the only causal event. It is also possible that closely related individuals are etiologically heterogeneous.
With the goal of minimizing heterogeneity that might confound mapping of major loci conferring risk for ASDs, we invested substantial effort to standardize all phases of this multicenter project, including phenotypic assessment, sample ascertainment, genotyping and analysis. Linkage analyses based on a three-level diagnostic scheme produce suggestive evidence for linkage in the vicinity of 11p12-p13 (Fig. 1) for one level: all families. Relative to appropriate baseline, evidence for linkage at 11p12-p13 is amplified in select subsets of the data: (i) subsets obtained by removing families containing one or more affected individuals inferred to carry CNV (Fig. 3); (ii) the set of families containing affected females (Fig. 4) and (iii) subsets of families based on both sex of affected individuals and presence of CNVs (Fig. 5) . For the subset of female-containing families without affected individuals who carry CNVs, the maximum Z lr increases to 4.03. We believe these explorations motivate thorough fine-mapping of the 11p12-p13 region. Figure 5 The effect on linkage of splitting families into female-containing and male-only families while also removing families in which affected individuals putatively carry CNVs. For female-containing families and the filtered subset, peaks localize to 9p24.1 (Z lr ¼ 3.32 at rs1575284; m-P ¼ 0.105) and 11p12 (Z lr ¼ 3.90 at rs1039205; m-P ¼ 0.411); for femalecontaining and the plate-by-plate subset, to 9p24.1 (Z lr ¼ 3.28 at rs1821892; m-P ¼ 0.295) and 11p12 (Z lr ¼ 3.48 at rs1039205; m-P ¼ 0.111); and for female-containing families and the batch subset, to 11p13 (Z lr ¼ 4.03 at rs1358054; m-P ¼ 0.014) and 15q23 (Z lr ¼ 3.30 at rs1433452; m-P ¼ 0.044).
been observed previously for this region, but 11p12-p13 has not been a major focus for discovery of autism risk loci. Several regions have been featured prominently in previous linkage analyses: namely 2q, 7q and 17q. Of these regions, 2q and 7q garner modest linkage support from families of European ancestry (Supplementary Fig. 4) , whereas the 17q linkage region does not. The largest linkage signal on 2q, Z lr ¼ 3.1, occurs for female-containing families in 2q31.1; the largest signal on 7q, Z lr ¼ 3.1, occurs for male-only families in 7q22.3. Several explanations are plausible for these results. First, the previous linkages could be false positives. Second, for linkage studies of complex disorders, statistics for identified linkage regions tend to be biased upward relative to that expected from the linked risk loci. Because of this bias, combining samples with mixed evidence for linkage and adding new families, as done here, will often diminish previously identified linkage signals. Third, studies could have collected samples that differ in heritable features tied to risk loci, exaggerating the heterogeneity already inherent in ASD. Stochastic variation combined with this heterogeneity could overwhelm the linkage signal.
None of our linkage results can be interpreted as 'statistically significant' because we have performed numerous analyses of the data. In fact, we performed 18 linkage analyses on the full sample and 18 using families of European ancestry. Because many of these analyses were performed on overlapping subsets of the data, we effectively performed the equivalent of four to five independent genome scans 34 .
Our CNV analyses detect a hemizygous deletion of coding exons from NRXN1 for a pair of affected siblings. Without other information, this finding might not be especially meaningful, in particular because of the prevalence of CNVs in the genome 21 . However, the alteration is a de novo event, and others 23 have reported rare missense variants in NRXN1 in individuals with ASD that are not found in over 500 controls. Moreover, NRXN1 interacts with neuroligins, for which rare mutations apparently generate risk for ASDs and mental retardation 14, 15 . Therefore, we have evaluated transmissions in our families for four NRXN1 SNPs (rs1363036, rs930752, rs1377238, rs2018909). Using the FBAT 35 empirical statistic, we have tested transmissions under additive and dominant models in all families and in the broad subset (dominant and recessive models are indistinguishable in this analysis). For all families, biased transmission is significant at two loci under the dominant model: the minor allele of rs1363036 (P ¼ 0.0091) and the major allele of rs930752 (P ¼ 0.025). (Only rs930752 showed significantly biased transmission under the additive model (P ¼ 0.014).) These SNPs are in modest LD (r 2 ¼ 0.048). In the broad subset, results are stronger for rs1363036 (dominant, P ¼ 0.0041) but are weaker for rs930752 (dominant, P ¼ 0.076; additive, P ¼ 0.072). These two SNPs, separated by 88 kb, are intronic and are unlikely to convey risk directly.
Accumulating evidence thus implicates a role for neurexins and neuroligins in ASDs. For communication of signal between neurons, postsynaptic receptors must oppose neurotransmitter release sites on presynaptic axons. Neurexins have been shown to induce postsynaptic differentiation in contacting dendrites, while neuroligins induce presynaptic differentiation in glutamatergic axons 36 . The neurexinneuroligin link is fundamentally important for glutamatergic synaptogenesis (and, apparently, GABAergic synaptogenesis 36, 37 ). Moreover, aberrant glutamate function is often cited as an important element of risk for ASDs 38, 39 , a hypothesis compatible with its role as the major excitatory neurotransmitter and critical factor in brain development 40 . Autism-like behaviors and diagnoses of autism are common for individuals with either Fragile-X syndrome or tuberous sclerosis, both of which are associated with dysregulated glutamate signaling 41, 42 .
Is oligogenic or 'major gene' variation associated with other glutamate-related genes? In addition to our results, intriguing evidence for association has been found for the mitochondrial aspartate/ glutamate carrier SLC25A12 (on 2q31) and GRIK2 (ref. 13) . Still, the protein product of SLC25A12 is a mitochondrial aspartate-glutamate carrier not known to affect glutamatergic synaptic function. Knockout of SLC25A12 in mice impairs myelination of neuronal cells resulting from limitations to aspartate delivery, not glutamate 43 . The protein product of GRIK2, GluR6, is an ionotropic kainate receptor that affects neuronal development. Based on its mapping to 6q16.3, it is not a positional candidate according to our results. For femalecontaining families, however, linkage results are modestly positive (Z lr ¼ 1.9 for all families and families of European ancestry; Z lr ¼ B2.40 for families retained using the batch method of CNV calling).
The UCSC Genome Browser lists 168 genes with descriptions containing the keyword 'glutamate' . Many fall in linkage regions, including 11p13-12 (SLC1A2 and PRRG4), 2q31 (SLC25A12), 4q28.3 (SLC7A11), 7q21.3 (SLC25A13), 9p24.2 (SLC1A1), 9q34.11 (FGPS) and 15q25.2 (HOMER2). Of ten glutamate solute carriers, half fall in the cited linkage regions (keywords 'glutamate' + 'solute' + 'carrier'), but not all are related to glutamatergic synaptic function. SLC1A1 and SLC1A2 fall close to linkage peaks, and their protein products affect glutamate synapse function and brain development; thus, they are excellent targets for positional candidate gene analyses.
METHODS
Linkage screening set. A SNP-based genome scan was conducted using the Affymetrix 10K v2 SNP array. Genotyping was contracted to the Translational Genomics Research Institute (TGEN). TGEN genotyped DNA samples falling into 1,496 nominal families, of which 1,168 could be used for linkage. Written permission was received from all adult participants and for all younger participants; procedures were approved by institutional review boards of all participating institutions.
Strategy for linkage analysis. For linkage analyses, we grouped families into three diagnostic classes: narrow, broad and heterogeneous ASD (hASD). To qualify for the narrow class, two or more affected individuals had to meet criteria for autism on both the ADI-R 18 and the ADOS 18 . For the broad category, at least one individual had to meet ADI-R criteria for autism and ADOS criteria for autism or ASD. At least one other family member had to meet criteria for impairment on the social or communication domains of the ADI-R and meet criteria for at least ASD on the ADOS. The hASD families were completely independent of the broad and narrow categories but were combined with the broad set to analyze linkage in all families. The hASD families consisted largely of either families that met ADI-R criteria for ASD or autism 18 but that did not undergo ADOS evaluation or families with multiple individuals per family who met ASD criteria by ADOS and demonstrated impairment on the social or communication domains of the ADI-R but did not meet full criteria for autism on the ADI-R. In addition to diagnostic categories, families were divided into subsets based on male-only or femalecontaining status.
Genetic quality control, tag SNP selection and ancestry. We evaluated three features of data quality: namely, degree of missing genotypes (missingness), mendelian errors and Hardy-Weinberg equilibrium (HWE). Individuals (20%) and loci (10%) with substantial missing data were not considered for linkage analyses because these features usually indicate poor DNA quality and problems with genotype calls, respectively. Likewise, loci with minor allele frequency (MAF) o 0.05 were discarded.
Mendelian errors were evaluated using PEDCHECK 44 . Loci showing multiple mendelian errors-for correct family structure-were discarded for linkage testing. To overcome possible problems arising owing to ancestry, we first selected tag SNPs and then evaluated HWE with the large sample inferred to be of homogeneous European ancestry. We analyzed linkage disequilibrium (LD) using HCLUST 45 ,  selecting tag SNPs to represent clusters of others in substantial LD (r 2 4 0.8). We chose those that were highly correlated with the other SNPs in the cluster; we estimated ancestry by using principal component analyses 33 and evaluated HWE using parental data. Loci were not used for analyses if HWE was rejected at a P-value o 0.005. Finally, we used MERLIN 46 to infer likely genotyping errors on the basis of apparent genetic recombination. When genotypes were likely to be errors (P o 0.01), they were set to 'missing' .
Linkage analysis. We used the BLUE method 47 to estimate allele frequencies. Linkage was estimated from the entire set of SNPs using MERLIN 46 and the exponential S-all statistic. Linkage was also estimated by using MERLIN 46 and ALLEGRO 48 from tag SNPs. We found virtually no difference in results using tag SNPs or all SNPs, with or without using the options in MERLIN to handle LD. We analyzed heterogeneity of linkage between strata using the methods of ref. 49 , which test for significant differences in shared IBD among affected siblings in families. We computed heterogeneity statistics in each region or setting in which a linkage trace crossed the threshold for suggestive linkage.
CNV assessment. CNVs were inferred from Affymetrix 10K array scans using dChip 2006 software (DNA Chip Analyzer) 50 . We have also used other algorithms, and the data will be posted at the Autism Chromosome Rearrangement Database as it is validated. Initially, 7,610 scans were available (this number exceeds the 6,709 samples genotyped for linkage since the CNV experiments continued after the initial data freeze). We excluded those samples with a genotype call rate o92% and/or an array percentage outlier of 45%, leaving 5,997 experiments suitable for CNV analyses. For the 'batch' analysis, we grouped the arrays into six cohorts of 1,000 samples each. The median probe intensities for the arrays varied greatly (o100 to 41,000), indicating the need for normalization to compare signals. Arrays were normalized at the probe intensity level using invariant set normalization to a baseline array within each group of 1,000 experiments 50 . A signal value was then calculated for each SNP using a model-based method and averaged across all samples for each SNP to obtain the mean signal of a diploid genome. The observed raw copy number was then defined and copy number inferred for each individual or SNP using a Hidden Markov Model 50 . As samples were submitted in 96-well plate formats and arrays were processed in the same manner, the 'batch' analysis contained plate-specific noise, apparently leading to many false positive CNV calls. In an attempt to increase the signal-to-noise ratio, we analyzed arrays in a 96-well plate-specific manner. For example, we excluded 12 plates having fewer than 40 samples after the initial filtering, leaving 5,823 scans for the plate analysis. Arrays were normalized within each set and copy number calculated in the same manner as was for the 'batch' analysis. We also excluded those samples with more than ten CNVs per sample from all analyses to avoid calling a high number of false positives. Because we had family data, certain CNV could be tentatively confirmed by using the family structure and mendelian errors (although the original CNV calls were blind to family status). Using these data as a benchmark, the 'plate' analysis produced a cleaner data set than the 'batch' analysis and was therefore parsed further using a combination of more stringent thresholds (fewer than five CNVs per sample) and manual curation of the raw data to give a 'filtered' data set. The inferred CNVs for all three data sets were interpreted on several levels. We also completed similar analysis for the X chromosome but did not include the results, as only 263 SNPs covered this segment of the genome (40 CNVs were found). Called CNVs were also examined for overlap with genomic features including mapped chromosome rearrangement breakpoints annotated in the Autism Chromosome Rearrangement Database and polymorphic CNVs in the Database of Genomic Variants. For all three analyses, affected individuals and families with CNVs that did not have complete overlap with the DGV were removed from linkage analysis.
Accession codes. Gene Omnibus Expression (GEO): raw data from the Affymetrix 10K experiments, GSE6754. Corrigendum: Variation in FTO contributes to childhood obesity and severe adult obesity
